{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:50Z","timestamp":1789972130626,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T00:00:00Z","timestamp":1376006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"name":"Ewha Global Top5 Grant 2013 of Ewha Womans University, Seoul, Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.bone.2013.08.005","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T18:45:58Z","timestamp":1376505958000},"page":"201-205","source":"Crossref","is-referenced-by-count":46,"title":["Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates"],"prefix":"10.1016","volume":"57","author":[{"given":"Jin-Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Ae","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Rae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.08.005_bb0005","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0010","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","article-title":"A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution","volume":"112","author":"Subramanian","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bone.2013.08.005_bb0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","article-title":"Epidemiology and pathogenesis of osteonecrosis of the jaw","volume":"8","author":"Reid","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2013.08.005_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1749-6632.2010.05770.x","article-title":"Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone","volume":"1218","author":"Cremers","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2013.08.005_bb0030","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0035","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0045","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bone.2013.08.005_bb0050","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ajoms.2012.06.007","article-title":"Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients","volume":"25","author":"Choi","year":"2013","journal-title":"J Oral Maxillofac Surg Med Pathol"},{"key":"10.1016\/j.bone.2013.08.005_bb0060","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.joms.2011.12.028","article-title":"Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases","volume":"70","author":"Morris","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0065","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.08.005_bb0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bone.2013.08.005_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.08.005_bb0080","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.08.005_bb0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.clinbiochem.2009.04.001","article-title":"Bone turnover markers in the management of postmenopausal osteoporosis","volume":"42","author":"Brown","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2013.08.005_bb0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.08.005_bb0105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdl045","article-title":"Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?","volume":"17","author":"Ardine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bone.2013.08.005_bb0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","article-title":"Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene","volume":"67","author":"Lehrer","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.08.005_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bone.2013.08.005_bb0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tripleo.2008.01.033","article-title":"Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws","volume":"106","author":"Lehrer","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bone.2013.08.005_bb0125","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.08.005_bb0130","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.bone.2013.08.005_bb0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S8756-3282(01)00592-0","article-title":"Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease","volume":"29","author":"Alvarez","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.08.005_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/art.1780400312","article-title":"Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity","volume":"40","author":"Alvarez","year":"1997","journal-title":"Arthritis Rheum"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T00:24:41Z","timestamp":1563668681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213003153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S8756328213003153"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.08.005","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}